The incidence of upper gastrointestinal haemorrhage within four months of renal transplantation was studied in two groups of patients. Thirty patients who received prophylactic cimetidine suffered no episodes of upper gastrointestinal haemorrhage, while six of the 33 patients who did not receive cimetidine suffered haemorrhages and one of them died as a result. The difference between the groups was significant. The results suggest that the prophylactic use of cimetidine in patients receiving renal transplants is worth while.
The period and nature of hazard in clinical renal transplantation. I. The hazard to patient survival
The role of histamine and histamine receptors in the pathogenesis and treatment of erosive gastritis
Antacid versus cimetidine in preventing acute gastrointestinal bleeding. A randomized trial in 75 critically ill patients
Randomized prospective evaluation of cimetidine and antacid control of gastric pH in the critically ill
Risk factors for clinically important upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group
Effect of cimetidine on upper gastrointestinal bleeding after renal transplantation: a prospective study
Histamine and stress ulcer: new components in organizing a sequential trial on cimetidine prophylaxis in seriously ill patients and definition of a special group at risk (severe polytrauma)
The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function
Prevention of recurrent ulcer bleeding, a multicentre study of the effect of ranitidine and trimipramine over one year
Allogenic & Autologous Therapies
Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.